摘要
目的:
通过免疫组织化学方法检测人肾细胞癌中Notch信号途径蛋白的表达水平,探究Notch信号途径分子与人肾细胞癌发生发展的可能关系,为临床寻找新的治疗肾细胞癌的靶点提供一定的方向和理论依据。
方法:
手术方法获得患者的肾细胞癌组织及癌旁组织标本,共8对,通过HE染色和免疫组织化学染色的方法对肾细胞组织和癌旁组织中Notch信号通路受体Notch-1、Notch-2和配体Jagged-1、Jagged-2蛋白表达水平进行检测。
结果:
癌症组织中Notch信号途径蛋白Notch-1、Jagged-1、Notch-2以及Jagged-2阳性率分别为22.5%、30%、65%和60%;癌旁组织中Notch信号途径蛋白Notch-1、Jagged-1、Notch-2以及Jagged-2阳性率分别为72.5%、67.5%、27.5%和20%,癌旁组织与癌症组织Notch-1、Jagged-1、Notch-2以及Jagged-2阳性率比较差异有统计学意义(P﹤0.05)。
结论:
1. Notch信号通路蛋白和人肾细胞癌的发生呈现出一定的关联性。
2. Notch信号通路的受体Notch-1和配体Jagged-1在人肾细胞癌组织中的表达阳性率明显低于癌旁组织,提示Notch-1和Jagged-1与肾细胞癌的发生呈现出了负相关。
3. Notch信号通路的受体Notch-2和配体Jagged-2在人肾细胞癌组织中的表达阳性率明显高于癌旁组织,提示Notch-2和Jagged-2与肾细胞癌的发生呈现出了正相关。
Objective:
Detecting the Notch signaling pathway related protein expression level by immunohistochemistry in human renal cell carcinoma,to explore the possible relationship between the Notch signaling pathway moleculars and the development of human renal cell cancer,providing some direction and theoretical basis for finding new targets in the clinical treatment of renal cell carcinoma.
Method:
Obtain of 8 pieces the renal cell carcinoma specimens by surgical methods, the Notch signaling receptor Notch-1, Notch-2 and ligand Jagged-1, Jagged-2 protein levels in renal cell tissue and renal cell carcinoma adjacent tissues were detected by HE and immunohistochemical staining methods.The results showed that there are some relevance of the occurrence of renal cell carcinoma and Notch signaling pathways, and that the Notch signaling pathway may be involved in the development of renal cell carcinoma.
Results:
The positive rate of the memberof Notch signaling pathway Notch-1, Jagged-1,Notch-2 and Jagged-2 was 22.5% , 30%, 65% and 60% , in renal cell carcinoma ,respectively. The positive rate of the member of Notch signaling pathway Notch-1, Jagged-1,Notch-2 and Jagged-2 was 72.5% , 67.5%, 27.5% and 20% , in renal cell carcinoma adjacent tissue,respectively. Compared with renal cell carcinoma adjacent tissue, the positive rate of the memberof Notch signaling pathway Notch-1, Jagged-1,Notch-2 and Jagged-2 have statistical significance in renal cell carcinoma(p﹤0.05).
Conclusion:
1. It showed that there are some relevance of the Notch signaling pathway protein and the development of human renal cell carcinoma .
2. Compared with the renal cell carcinoma adjacent tissue, the expression levels of the Notch signaling and Notch-1 receptor ligand Jagged-1 in the cancer tissue were significantly lower, suggesting that there is a negative relevance of Notch-1 and Jagged-1 with the development of renal cell carcinoma.
3. Compared with the renal cell carcinoma adjacent tissue, the expression levels of Notch-2, another receptor of Notch signaling pathway, and its ligand Jagged-2 in the cancer tissue were significantly higher, suggesting that there is a positive relevance of Notch-1 and Jagged-1 with the development of renal cell carcinoma.
引文
[1]Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane.Cell 1997;90:281-91.
[2]Wharton KA, Yedvobnick B, Finnerty VG, Artavanis-Tsakonas S. opa: a novel family of transcribed repeats shared by the Notch locus and other developmentally regulated loci in D. melanogaster. Cell 1985;40:55-62.
[3]Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrinmetalloprotease TACE. Molecular Cell 2000;5:207-16.
[4]Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, et al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Molecular Cell 2000;5:197-206.
[5]De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999;398:518-22.
[6]Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligandinduced proteolytic release of intracellular domain. Nature 1998; 393:382-6.
[7]Wu L, Griffin JD. Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Seminars in Cancer Biology 2004;14:348-56.
[8]Wallberg AE, Pedersen K, Lendahl U, Roeder RG. p300 and PCAF act cooperatively to mediate transcriptional activation from chromatin templates by notch intracellular domains in vitro. Molecular and Cellular Biology 2002;22:7812-9.
[9]Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. Journal of Cellular Physiology 2003;194:237-55.
[10]Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Molecular and Cellular Biology 2001;21: 5925-34.
[11]Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. The EMBO Journal 2001;20:3427-36.
[12]Cheng P, Zlobin A, Volgina V, Gottipati S, Osborne B, Simel EJ, et al. Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells. Journal of Immunology 2001;167:4458-67.
[13]Reizis B, Leder P. Direct induction of T lymphocyte-specific gene expression by the mammalian Notch signaling pathway. Genes & Development 2002;16:295-300.
[14]Amsen D, Antov A, Jankovic D, Sher A, Radtke F, Souabni A, et al. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity 2007;27:89-99.
[15]Lamar E, Deblandre G, Wettstein D, Gawantka V, Pollet N, Niehrs C, et al. Nrarp is a novel intracellular component of the Notch signaling pathway.Genes & Development 2001;15:1885-99.
[16]Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes & Development 2006;20:2096- 109.
[17]Izon DJ, Aster JC, He Y,Weng A, Karnell FG, Patriub V, et al. Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizingNotch1. Immunity 2002;16:231-43.
[18]Martinez Arias A, Zecchini V, Brennan K. CSL-independent Notch signalling: a checkpoint in cell fate decisions during development? Current Opinion in Genetics & Development 2002;12:524-33.
[19]Deftos ML, Huang E, Ojala EW, Forbush KA, Bevan MJ. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity 2000;13:73-84.
[20]Kopan R, Nye JS, Weintraub H. The intracellular domain of mouse Notch: a constitutively activated repressor of myogenesis directed at the basic helixloop-helix region of MyoD. Development (Cambridge England) 1994;120:96-2385.
[21]Wilkin MB, Carbery AM, Fostier M, Aslam H, Mazaleyrat SL, Higgs J, et al.Regulation of notch endosomal sorting and signaling by Drosophila Nedd4 family proteins. Current Biology 2004;14:2237-44.
[22]Lai EC. Protein degradation: four E3s for the notch pathway. Current Biology 2002;12:R74-8.
[23]Le Borgne R, Remaud S, Hamel S, Schweisguth F. Two distinct E3 ubiquitin ligases have complementary functions in the regulation of delta and serrate signaling in Drosophila. PLoS Biology 2005;3:e96.
[24]Sakata T, Sakaguchi H, Tsuda L, Higashitani A, Aigaki T, Matsuno K, et al.Drosophila Nedd4 regulates endocytosis of notch and suppresses its ligandindependent activation. Current Biology 2004;14:2228-36.
[25]Nie J,McGillMA, DermerM, Dho SE,Wolting CD,McGlade CJ. LNX functions as a RING type E3 ubiquitin ligase that targets the cell fate determinant Numb for ubiquitin-dependent degradation. The EMBO Journal 2002;21:93-102.
[26]Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis.Journal of Mammary Gland Biology and Neoplasia2004;9:145-63.
[27]Bruckner K, Perez L, Clausen H, Cohen S. Glycosyltransferase activity of Fringe modulates Notch-Delta interactions. Nature 2000;406: 411-5.
[28]Kidd S, Lieber T, Young MW. Ligand-induced cleavage and regulation of nuclear entry of Notch in Drosophila melanogaster embryos. Genes & Development1998;12:3728-40.
[29]Haines N, Irvine KD. Glycosylation regulates Notch signalling. Nature Reviews 2003;4:786-97.
[30]Kidd S, Baylies MK, Gasic GP, Young MW. Structure and distribution of the Notch protein in developing Drosophila. Genes & Development 1989;3:1113-29.
[31]Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Molecular Cancer Therapeutics 2006;5: 483-93.
[32]Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al.JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Research 2004;64:6854-7.
[33]Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. The Journal of Clinical Investigation 2005;115: 3166-76.
[34]Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nature Genetics 2003;33:416-21.
[35]Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken bychromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66: 649-61.
[36]Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (New York NY) 2004;306:71-269.
[37]Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih Ie M, et al.Amplicon profiles in ovarian serous carcinomas. International Journal of Cancer 2007;120:2613-7.
[38]Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis.The Journal of Cell Biology 2004;167:215-21.
[39]Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphobla- stic leukemia.Blood 2007;110:278-86.
[40]Palomero T, McKenna K, ON J, Galinsky I, Stone R, Suzukawa K, et al.Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia 2006;20:1963-6.
[41]Fu L, Kogoshi H, Nara N, Tohda S. NOTCH1 mutations are rare in acute myeloid leukemia. Leukemia & Lymphoma 2006;47:2400-3.
[42]Chiaramonte R, Basile A, Tassi E, Calzavara E, Cecchinato V, Rossi V, et al. A wide role for NOTCH1 signaling in acute leukemia. Cancer Letters 2005;219:113-20.
[43]Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leukemia & Lymphoma 2001;42:467-72.
[44]Tohda S, Kogoshi H, Murakami N, Sakano S, Nara N. Diverse effects of the Notch ligands Jagged1 and Delta1 on the growth and differentiation of primary acute myeloblastic leukemia cells. Experimental Hematology 2005;33:558-63.
[45]Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, et al.Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009;113:856-65.
[46]Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J, MacDonald HR, et al.Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999;10:547-58.
[47]Lee SY, Kumano K, Nakazaki K, Sanada M, Matsumoto A, Yamamoto G, et al.Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Science 2009;100:920-6.
[48]Troen G, Wlodarska I, Warsame A, Hernandez Llodra S, De Wolf-Peeters C,Delabie J. NOTCH2 mutations in marginal zone lymphoma. Haematologica 2008;93:1107-9.
[49]Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M,Mathas S, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511-5.
[50]Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, Carpenter AC, et al.Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005;106:3898-906.
[51]Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bonemarrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004;103:3503-10.
[52]Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002;99:3398-403.
[53]Souabni A, Cobaleda C, Schebesta M, Busslinger M. Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity 2002;17:781-93.
[54]Tanigaki K, Kuroda K, Han H, Honjo T. Regulation of B cell development by Notch/RBP-J signaling. Seminars in Immunology 2003;15: 113-9.
[55]Proweller A, Tu L, Lepore JJ, Cheng L, Lu MM, Seykora J, et al. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Research 2006;66:7438-44.
[56]Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009;16:55-66.
[57]Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Research 2006;66:4182-90.
[58]Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Research 2009;69:5312-20.
[59]Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. The Journal of Clinical Investigation 2008;118:3660-70.
[60]Gallahan D, Callahan R. Mammary tumorigenesis in feral mice: identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. Journal of Virology 1987;61:66-74.
[61]Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 1999;18:5973-81.
[62]Raafat A, Bargo S, Anver MR, Callahan R. Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh). Oncogene 2004;23:9401-7.
[63]Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS.A putative human breast stem cell population is enriched for steroid receptor-positive cells. Developmental Biology 2005;277:443-56.
[64]Parr C,Watkins G, JiangWG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. International Journal of Molecular Medicine 2004;14:779-86.
[65]Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. Highlevel coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Research 2005;65:8530-7.
[66]Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, et al.Activation of Notch-1 signaling maintains the neoplastic phenotype inhuman Ras-transformed cells. Nature Medicine 2002;8:979-86.
[67]Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (New York NY) 1985;230:9-1132.
[68]Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008;27:5019-32.
[69]Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A,et al. Dominant-negative Notch3 receptor inhibits mitogen- activated protein kinase pathway and the growth of human lung cancers. Cancer Research 2005;65:3555-61.
[70]Konishi J, Yi F, Chen X, Vo H, Carbone DP, Dang TP. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene 2009.
[71]Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L,et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Research 2007;67:7954-9.
[72]Zheng Q, Qin H, Zhang H, Li J, Hou L, Wang H, et al. Notch signaling inhibits growth of the human lung adenocarcinoma cell line A549. Oncology Reports 2007;17:847-52.
[73]Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, et al.Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Research 2001;61:3200-5.
[74]Sriuranpong V, Borges MW, Strock CL, Nakakura EK, Watkins DN, Blaumueller CM, et al. Notch signaling induces rapid degradation of achaete-scute homolog1. Molecular and Cellular Biology 2002;22:3129-39.
[75]Parkin DM. Cancer in developing countries. Cancer Surveys 1994;19-20:519-61.
[76]Goodlad RA, Ryan AJ, Wedge SR, Pyrah IT, Alferez D, Poulsom R, et al.Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.Carcinogenesis 2006;27:2133-9.
[77]Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, et al. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proceedings of the National Academy of Sciences of the United States of America 2007;104:10625-30.
[78]Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991;129:896-900.
[79]Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nature Reviews Cancer 2007;7:327-31.
[80]Indraccolo S, Minuzzo S, Masiero M, Pusceddu I, Persano L,Moserle L, et al.Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Research 2009;69:1314-23.
[81]Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells:implications for modulating arteriogenesis and angiogenesis. Molecular and Cellular Biology 2003;23:14-25.
[82]Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Research 2005;65: 8690-7.
[83]Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, et al. Expression of deltalike ligand 4 (Dll4) and markers of hypoxia in colon cancer. British Journal of Cancer 2009;101:1749-57.
[84]Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB, et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.Cancer Research 2009;69:573-82.
[85]Reedijk M, Odorcic S, Zhang H, Chetty R, Tennert C, Dickson BC, et al.Activation of Notch signaling in human colon adenocarcinoma. International Journal of Oncology 2008;33:1223-9.
[86]Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA,et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3: 565-76.
[87]Sawey ET, Johnson JA, Crawford HC. Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proceedings of the National Academy of Sciences of theUnited States of America 2007;104:19327-32.
[88]Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, et al.Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clinical Cancer Research 2009;15:2291-301.
[89]Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Research 2009;69:2757-65.
[90]Yao J, Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt- dependent pathway.Medical Oncology (Northwood London England) 2009. doi: 10.1007/s12032-009-9326-5.L. Yin et al. / Biochemical Pharmacology 80 (2010) 690-701 699.
[91]Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al.Notch promotes radioresistance of Glioma stem cells. Stem Cells (Dayton OH) 2009;28:17-28.
[92]Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. Notch pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (Dayton OH) 2009;28:5-16.
[93]Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
[94]Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005;8:13-23.
[95]Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, et al.Haploinsufficiency of delta-like 4 ligand results inembryonic lethality due to major defects in arterial and vascular development. Proceedings of the National Academy of Sciences of the United States of America 2004;101:15949-54.
[96]Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes & Development 2004;18:2469-73.
[97]Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al.Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
[98]Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD,et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proceedings of the National Academy of Sciences of the United States of America 2007;104:3219-24.
[99]Suchting S, Freitas C, le Noble F, Benedito R, Breant C, Duarte A, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proceedings of the National Academy of Sciences of the United States of America 2007;104:3225-30.
[100]Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, et al.Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007;109: 4753-60.
[101]Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW,et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7.
[102]Ridgway J, Zhang G,Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.Nature 2006;444:1083-7.
[103]Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, etal. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Research 2007;67:11244-53.
[104]Fung E, Tang SM, Canner JP, Morishige K, Arboleda-Velasquez JF, Cardoso AA,et al. Delta-like 4 induces notch signaling in macrophages: implications for inflammation. Circulation 2007;115:2948-56.
[105]Maillard I, Adler SH, Pear WS. Notch and the immune system. Immunity 2003;19:781-91.
[106]Mukherjee S, Schaller MA, Neupane R, Kunkel SL, Lukacs NW. Regulation of T cell activation by Notch ligand DLL4, promotes IL-17 production and Rorc activation. Journal of Immunology 2009;182:73818.
[107]Lichtenthaler SF, Ida N, Multhaup G, Masters CL, Beyreuther K. Mutations in the transmembrane domain of APP altering gamma-secretase specificity.Biochemistry 1997;36:15396-403.
[108]O’Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH, et al.Activating Notch1 mutations in mouse models of T-ALL. Blood 2006;107:781-5.
[109]Lewis HD, Leveridge M, Strack PR, Haldon CD, O’Neil J, Kim H, et al. Apoptosisin T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chemistry & Biology 2007;14:209-19.
[110]Masuda S, Kumano K, Suzuki T, Tomita T, Iwatsubo T, Natsugari H, et al. Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. Cancer Science 2009;100: 2444-50.
[111]Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas.Cancer Research 2004;64:7794-800.
[112]van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al.Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435:959-63.
[113]Rasul S, Balasubramanian R, Filipovic A, Slade MJ, Yague E, Coombes RC.Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. British Journal of Cancer 2009;100: 1879-88.
[114]Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008;111:2220-9.
[115]Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Research 2009;69:7672-80.
[116] O’Neil J, Grim J, Strack P, Rao S, Tibbitts D,Winter C, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gammasecretase inhibitors. The Journal of Experimental Medicine 2007;204:1813-24.
[117]Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.Nature Medicine 2007;13:1203-10.
[118]Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle (Georget- own Tex) 2008;7:70-965.
[119]Liu S, Breit S, Danckwardt S, Muckenthaler MU, Kulozik AE. Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Annals ofHematology 2009;88:613-21.
[120]Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, et al.Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature Medicine 2009; 15:50-8.
[121]Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits betaamyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. The Journal of Biological Chemistry 2004;279:12876-82.
[122]Barten DM, Meredith Jr JE, Zaczek R, Houston JG, Albright CF. Gammasecretase inhibitors for Alzheimer’s disease: balancing efficacy and toxicity.Drugs in R&D 2006;7:87-97.
[123]Lleo A. Activity of gamma-secretase on substrates other than APP. Current Topics in Medicinal Chemistry 2008;8:9-16.
[124]Shelton CC, Zhu L, Chau D, Yang L, Wang R, Djaballah H, et al. Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2009;106:20228-33.
[125]Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77.
[126]Li K, Li Y, Wu W, Gordon WR, Chang DW, Lu M, et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. The Journal of Biological Chemistry 2008;283:8046-54.
[127]Yan M, Plowman GD. Delta-like 4/Notch signaling and its therapeutic implications.Clinical Cancer Research 2007;13:7243-6.
[128]Jin YH, Kim H, Oh M, Ki H, Kim K. Regulation of Notch1/NICDand Hes1 expressions by GSK-3alpha/beta. Molecules and Cells 2009;27: 15-9.
[129]Espinosa L, Ingles-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. The Journal of Biological Chemistry 2003;278: 32227-35.
[130]Nagaraj R, Banerjee U. Regulation of Notch and Wingless signalling by phyllopod, a transcriptional target of the EGFR pathway. The EMBO Journal 2009;28:337-46.
[131]Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends in Cell Biology 2007;17:118-26.
[132]Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Research 2009;69:7569-76.
[133]Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009;4:e6816.
[134]Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, et al.MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 2009;4:e4998.
[135]Cohen B, Shimizu M, Izrailit J, Ng NF, Buchman Y, Pan JG, et al. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Research and Treatment 2009.
[136]Ono Y, Gnocchi VF, Zammit PS, Nagatomi R. Presenilin-1 acts via Id1 to regulate the function of muscle satellite cells in a gamma-secretase- independent manner. Journal of Cell Science 2009;122:4427-38.
[137]Eitoku M, Sato L, Senda T, Horikoshi M. Histone chaperones: 30years from isolation to elucidation of the mechanisms of nucleosome assembly and disassembly. Cellular and Molecular Life Sciences 2008; 65: 414-44.
[138]De Koning L, Corpet A, Haber JE, Almouzni G. Histone chaperones: an escort network regulating histone traffic. Nature Structural & Molecular Biology 2007;14:997-1007.
[139]Goodfellow H, Krejci A, Moshkin Y, Verrijzer CP, Karch F, Bray SJ. Genespecific targeting of the histone chaperone asf1 to mediate silencing. Developmental Cell 2007;13:593-600.
[140]Moshkin YM, Kan TW, Goodfellow H, Bezstarosti K, Maeda RK, Pilyugin M,et al. Histone chaperones ASF1 and NAP1 differentially modulate removal of active histone marks by LID-RPD3 complexes during NOTCH silencing.Molecular Cell 2009;35:782-93.
[141]Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007; 128:735-45.
[142]Martinez AM, Schuettengruber B, Sakr S, Janic A, Gonzalez C, Cavalli G.Polyhomeotic has a tumor suppressor activity mediated by repression of Notch signaling. Nature Genetics 2009;41:1076-82.
[143]Fontana JR, Posakony JW. Both inhibition and activation of Notch signaling rely on a conserved neuralized-binding motif in Bearded proteins and the Notch ligand Delta. Developmental Biology 2009;333:373-85.
[144]He F, Saito K, Kobayashi N, Harada T, Watanabe S, Kigawa T, et al. Structural and functional characterization of the NHR1 domain of the Drosophila neuralized E3 ligase in the notch signaling pathway. Journal of Molecular Biology 2009;393:478-95.
[145]Okajima T, Irvine KD. Regulation of notch signaling by o-linked fucose. Cell 2002;111:893-904.
[146]Stahl M, Uemura K, Ge C, Shi S, Tashima Y, Stanley P. Roles of Pofut1 and Ofucose in mammalian Notch signaling. The Journal of Biological Chemistry 2008;283:13638-51.
[147]van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M.Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. The Journal of Biological Chemistry 2009;284:31018-27.
[148]Delwig A, Rand MD, Kuz. TACE can activate Notch independent of ligand.Cellular and Molecular Life Sciences 2008;65:2232-43.
[149]Bozkulak EC,Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Molecular and Cellular Biology 2009;29:5679-95.
[150]Maillard I, Weng AP, Carpenter AC, Rodriguez CG, Sai H, Xu L, et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions.Blood 2004;104:1696-702.
[151]Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Molecular and Cellular Biology 2003;23: 655-64.
[152]Nam Y, Sliz P, Song L, Aster JC, Blacklow SC. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 2006;124:973-83.
[153]Wilson JJ, Kovall RA. Crystal structure of the CSL-Notch- Mastermind ternary complex bound to DNA. Cell 2006;124:985-96.
[154]Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, et al.Direct inhibition of the NOTCH transcription factor complex. Nature 2009;462:182-8.
[155]Arora PS, Ansari AZ. Chemical biology: a Notch above other inhibitors. Nature 2009;462:171-3.
[156]Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Research 2004;64:7787-93.
[157]Hu C, Dievart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. The American Journal of Pathology 2006;168:973-90.
[158]Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008;27:5132-7.
[159]吴晶,秦叔逵.舒尼替尼治疗转移性肾细胞癌的临床药物经济学研究进展[J].临床肿瘤学杂志,2009,14(9):769-776.
[160]宋勇波,杨嗣星,赵战魁,等.VEGF和PCNA在肾细胞癌中的表达及意义[J].现代泌尿生殖肿瘤杂志,2009,1(6):360-3.
[161]National Cancer Institute Kidney Cancer Homepage [OL].2009[2009-08-09]. http: / /www. cancer. gov/ cancertop ics/ types/ kidney.
[162]Levi F, Lucchini F, Negri E, et al. Decliningmortality from kidney cancer in Europe[J]. Ann Oncol, 2004,15:1130-5.
[163]Ling Yin , Omaida C. Velazquez , Zhao-Jun Liu. Notch signaling: Emerging molecular targets for cancer therapy[J]. Biochemical Pharma- cology, 2010,80:690-701.
[164]Gray,G.E. et al. (1999) Human ligands of the Notch receptor. Am. J. Surg.Pathol., 154, 785-794.
[165]Tanimizu,N. et al. (2004) Notch signaling controls hepatoblast differentiationby altering the expression of liver-enriched transcription factors.J. Cell Sci., 117, 3165-3174.
[166]Ling Yin, Omaida C. Velazquez, Zhao-Jun Liu. Notch signaling: Emerging molecular targets for cancer therapy[J]. Biochemical Pharma-cology, 2010,80:690-701.
[167]Nijjar,S. et al. (2001) Notch receptor expression in adult human liver:a possible role in bile duct formation and hepatic neovascularisa- tion.Hepatology, 34, 1184-1192.
[168]Meng,R.D. et al. (2009) c-Secretase inhibitors abrogate oxaliplatininducedactivation of the Notch-1 signaling pathway in colon cancer cellsresulting in enhanced chemosensitivity. Cancer Res., 69, 573-582.
[169]付亚娟,叶枫,等。Notch信号通路的研究现状医学分子生物学杂志, 2007, 4 (5) : 4472450 J MedMol Biol, 2007, 4 (5) : 4472450
[170]Thompson CB. Apoptosis in the Pathogenesis and treatment of disease [J]. Seience. 1995; 267(10): 1456-1462.
[171]Kerbl K, Figenshau RS, Clayman RV, Chandhoke PS, Kavoussi LR, Albala DM, Stone AM.Retroperitoneal laparoscopic nephrectomy: laboratory and clinical experience. J Endourol. 1993 ;7(1):23-26.
[172]王惠君,王海,李汉忠,等.转移性肾癌的免疫化学疗法[J].中华外科杂志,2004,42(4):205-206
